Influence of Acetylator Status on Sulphasalazine Efficacy and Toxicity in Patients with Rheumatoid Arthrftis

References

• McConkey B, Amos R S, Butler E P, Crockson R A, Crock-Son A P, Walsh L. Sulphasalazine in rheumatoid arthritis. Br. Med. J. 1980; 280: 4424
   Google Scholar
• Neumann V C, Grindulis K A, Hubball S, McConkey B, Wright V. Comparison between penicillamine and sulphasalazine in rheumatoid arthritis. Leeds-Birmingham trial. Br. Med. J. 1983; 227: 109, !+102
   Google Scholar
• Pullar T, Hunter J A, Capell HA. Sulphasalazine in rheumatoid arthritis: a double-blind comparison of sulphasalazine with placebo and sodium aurothiomalate. Br. Med. J. 1983; 287: 1102–4
   PubMed Web of Science ®Google Scholar
• Farr M, Tunn E J, Crockson A P, Bacon PA. The long term effects of sulphasalazine in the treatment of rheumatoid arthritis and a comparative study with penicillamine. Clin. Rheumatol. 1984; 3: 473–82
   PubMed Web of Science ®Google Scholar
• Bax D E, Amos R.S. Sulphasalazine: a safe, effective agent for prolonged control of rheumatoid arthritis. A comparison with aurothiomalate. Ann. Rheum. Dis. 1985; 44: 194–9
   PubMedGoogle Scholar
• Grindulis K A, McConkey B. The outcome of attempts to continue treatment with gold, penicillamine, sulphasalazine or dapsone for 2 years in rheumatoid arthritis. Ann. Rheum. Dis. 1984; 43: 398401
   Google Scholar
• Pullar T, Hunter J A, Capell HA. Effect of sulphasalazine on the radiological progression of rheumatoid arthritis. Ann. Rheum. Dis. 1987; 46: 398–402
   PubMed Web of Science ®Google Scholar
• Farr M, Kitas G D, Bacon PA. Assessing the outcome of sulphasalazine therapy in rheumatoid arthritis. Br. J. Rheumatol. 1987; 26: 3
   PubMedGoogle Scholar
• Situnayake D, Grindulis K A, McConkey B. Long term treatment of rheumatoid arthritis with sulphasalazine, gold or penicillamine. A comparison using life table methods. Ann. Rheum. Dis. 1987; 461: 177–83
   Google Scholar
• Farr M, Waterhouse L, Bacon PA. 5-year outcome of rheumatoid patients treated with sulphasalazine (SASP). Br. J. Rheumatol. 1989; 28: 2
   Google Scholar
• Pullar T, Hunter J A, Capell HA. Toxicity of sulphasalazine in patients with rheumatoid arthritis. Br. J. Rheumatol. 1985; 24: 214
   Google Scholar
• Farr M, Scott D GI, Bacon PA. Side effect profile of 200 patients with inflammatory arthritis treated with sulphasalazine. Drugs 1986; 32: 49–53, suppl. 1
   PubMed Web of Science ®Google Scholar
• Amos R S, Pullar T, Bax D E, Situnayake D, Capell H A, McConkey B. Sulphasalazine for rheumatoid arthritis. Toxicity in 774 patients monitored for 1 to 11 years. Br. Med. J. 1986; 293: 420–3
   PubMedGoogle Scholar
• Donovan S, Hawley S, MacCarthy J, Scott DL. Tolerabil-ity of enteric-coated sulphasalazine in rheumatoid arthritis: results of a co-operating clinics study. Br. J. Rheumatol. 1990; 29: 2014
   Google Scholar
• Peppercorn MA. Sulphasalazine: Pharmacology, clinical use. toxicity and related new drug development. Ann. Intern Med. 1984; 3: 377–86
   Web of Science ®Google Scholar
• Lunde P KM, Frislid K, Hansteen V. Disease and acetyla-tor polymorphism. Handbook of clinical pharmacokinetics., M. Gibaldi, L. Prescott. Adis Health Science Press, Australia 1983
   Google Scholar
• Azad Khan A K, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977; 289: 2–5
   Google Scholar
• Azad Khan A K, Truelove SC. Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. Gut 1980; 21: 232–41
   PubMed Web of Science ®Google Scholar
• Das K M, Eastwood M A, McManus J PA, Sirius W. Adverse reactions during salicyllazosulphapyridine therapy and the relation with drug metabolism and acetylator phe-notype. N. Engl. J. Med. 1973; 289: 491–5
   PubMed Web of Science ®Google Scholar
• Das K M, Eastwood MA. Acetylation polymorphism of sulphapyridine in patients with ulcerative colitis and Crohn's disease. Clin. Pharmacol. Ther. 1975; 18: 514–20
   PubMed Web of Science ®Google Scholar
• Pullar T, Hunter J A, Capell HA. Which component of sulphasalazine is active in rheumatoid arthritis?. Br. Med. J. 1985; 290: 1535–8
   PubMedGoogle Scholar
• Farr M, Broderick A, Bacon PA. Plasma and synovial fluid concentration of sulphasalazine and 2 of its metabolites in rheumatoid arthritis. Rheumatol.Int. 1985; 5: 247–51
   PubMedGoogle Scholar
• Pullar T, Hunter J A, Capell HA. Effect of acetylator phenotype on efficacy and toxicity of sulphasalazine in rheumatoid arthritis. Ann. Rheum. Dis. 1985; 44: 831–7
   PubMed Web of Science ®Google Scholar
• Bax D E, Greaves M S, Amos RS. Sulphasalazine for rheumatoid arthritis: relationship between dose, acetylator phenotype and response to treatment. Br. J. Rheumatol. 1986; 25: 282–4
   PubMedGoogle Scholar
• Carrol G. A comparative study of sulphasalazine and penicillamine in rheumatoid arthritis. Aust. NZ J. Med. 1983; 13: 212–6
   Google Scholar
• Schroder H. Simplified method for determining acetylator phenotype. Br. Med. J. 1972; 30: 506–7
   Google Scholar
• Ropes MW. Diagnostic criteria for rheumatoid arthritis: 1958 revision. Ann. Rheum. Dis. 1959; 18: 49–54
   PubMed Web of Science ®Google Scholar
• Pullar T, Hunter J A, Capell HA. Sulphasalazine in the treatment of rheumatoid arthritis: relationship of dose and serum levels in efficacy. Br. J. Rheumatol. 1985; 24: 269–76
   PubMedGoogle Scholar
• Farr M, Symmons D PM, Bacon PA. Raised serum alkaline phosphatase and aspartatc transaminase levels in 2 rheumatoid patients treated with sulphasalazine. Ann. Rheum.Dis. 1985; 44: 798–800
   PubMedGoogle Scholar
• Losec J D, Werlin SI. Sulphasalazine hepatotoxicity. Ann. J. Dis. Med. 1981; 135: 1070–2
   Google Scholar